Drug Policy Watch · State Brief 2026

Pennsylvania

Snapshot (structured)

Adult-use cannabis: Not legal. Repeated legalization pushes have failed to clear the split legislature, most recently in 2025 and 2026, and legalization was excluded again from the state budget signed July 12, 2026.
Medical cannabis: Legal since 2016 (Act 16). Roughly 440,000 active patients, about 185 dispensaries and 30 growers/processors, no sales tax on medical product.
Home grow: Prohibited for all, including medical patients. Cultivating even a single plant is a criminal offense. Legislation to allow patient home grow has been proposed but not passed.
Intoxicating hemp / hemp THC: Currently largely unregulated at the state level (delta-8, delta-10, THCA sold widely). A 2026 Senate bill (SB 49) to ban most intoxicating hemp products failed final passage 23 to 27 on June 10, 2026; a motion to reconsider passed, with no further action as of July 16, 2026.
Psychedelics: Illegal. Psilocybin is Schedule I. Narrow FDA-contingent and research/veteran-focused bills are pending, no decriminalization.
Broad decriminalization: No statewide decriminalization. Several cities (Philadelphia, Pittsburgh, others) have locally reduced small-amount cannabis penalties, but state law still criminalizes possession.
Harm reduction: Fentanyl test strips legal since 2022 (Act 111). Statewide syringe services NOT authorized by statute; PA is one of about 12 states without explicit statutory authorization. Naloxone access broadened via standing order.
Governor (party): Josh Shapiro (Democrat).
Legislature control: Split. House Democratic (102-100, one seat vacant), Senate Republican (27-23).
Citizen ballot initiatives allowed: No. Pennsylvania has no statewide citizen initiative or referendum process.
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis is not legal in Pennsylvania as of July 2026. Medical cannabis has been legal since the 2016 passage of Act 16 (the Medical Marijuana Act). The medical program is mature: approximately 440,000 active patients, about 185 dispensaries and 30 growers/processors, coverage of roughly two dozen qualifying conditions, telehealth certification, and no sales tax on medical product. Sales topped $1.3 billion in the first three quarters of 2025, up more than 4 percent year over year, even as patient prices have fallen sharply (reported down about 49 percent since 2021). Sources: Axios Philadelphia, MMJ.com guide, MPP Pennsylvania.

Home cultivation is prohibited for everyone, including registered medical patients; growing a single plant is a criminal offense. Legislation to allow medical patient home grow has been floated but not enacted. Source: MMJ.com guide.

Market structure: the medical market is concentrated among a limited set of vertically integrated operators and multistate operators (MSOs), with a capped number of grower/processor and dispensary permits issued under Act 16. The state has also created a microgrower/limited-license pathway intended to broaden participation, though the medical permit regime remains tightly limited. Source: Cannabis Industry Lawyer microgrower guide.

The ongoing adult-use debate is the central 2025-2026 cannabis story and it splits along the retail-model question. In May 2025 the Democratic-led House passed HB 1200, a state-store (government-run retail) legalization model, by a single party-line vote. The Republican-controlled Senate Law and Justice Committee killed it days later on a 7-3 vote, with even pro-legalization Republican committee chair Dan Laughlin opposing the state-store approach. Senators Laughlin (R) and Sharif Street (D) then introduced SB 120, a bipartisan bill for a privately operated, state-licensed market governed by a new Cannabis Control Board. As of early-to-mid 2026, SB 120 had not been scheduled for a hearing. Governor Shapiro again included adult-use legalization in his budget address (his prior proposals targeted revenue, restorative-justice funding, expungement, and small-business support). Sources: MJBizDaily, Pennsylvania Capital-Star, MPP SB 120 summary, Foley Hoag.

The 2026 session settled the question for the year. On June 29, 2026, all 23 Senate Democrats filed Discharge Resolution 4 to force SB 120 out of the Law and Justice Committee; the resolution has produced no floor action, and SB 120 remains in committee. On July 12, 2026, Governor Shapiro signed a $50.85 billion budget that does not mention cannabis, leaving legalization out again; Senate Majority Leader Joe Pittman called legalization a nonstarter in the negotiations. The November 2026 governor’s race now carries the question: State Treasurer Stacy Garrity, Shapiro’s Republican challenger, told NBC10 Philadelphia she would veto a legalization bill, answering yes when asked directly and saying she does not support legalizing recreational marijuana. Drug Policy Watch traced how each of Pennsylvania's routes to legalization closed this year, and why the November governor's race is the last one open, in Every Door but One. Sources: PA General Assembly (D.R. 4), Gov. Shapiro budget release, Pennsylvania Capital-Star, Cannabis Business Times, Philadelphia Inquirer.

Hemp

Intoxicating hemp-derived THC products, including delta-8, delta-10, and THCA, are currently sold widely in Pennsylvania with little state oversight. Under existing law these are permitted if derived from hemp and containing less than 0.3 percent delta-9 THC by dry weight. Source: Cannabis Regulations AI.

In March 2026 the Senate Law and Justice Committee amended SB 49, a bill creating a Cannabis Control Board to oversee medical cannabis and hemp, to add provisions banning most intoxicating hemp products. The amendment would bar hemp products exceeding 0.3 percent delta-9 THC by dry weight or 0.4 milligrams of total THC per container, explicitly aligning state law with the new federal hemp standard. SB 49 is sponsored by Senate Law and Justice Chair Dan Laughlin (R-Erie). The ban drew support from the Pennsylvania Cannabis Coalition, the Pennsylvania Chamber of Business and Industry, the Pennsylvania District Attorneys Association, and Attorney General David Sunday, and strong opposition from hemp retailers. On June 10, 2026, SB 49 failed final passage in the Senate, 23 votes to 27, but a motion to reconsider then passed 29-21; no further action had been taken as of July 16, 2026. Laughlin attributed the failure to Governor Shapiro asking Senate Democrats to vote no. Sources: PA General Assembly (SB 49 roll calls), Marijuana Moment (amendment), Sen. Laughlin SB 49 amendment release, Marijuana Moment (Senate rejects, may be revived), Sen. Laughlin (SB 49 fails), Cannabis Business Times.

Federal exposure is significant. Section 781 of the Continuing Appropriations and Extensions Act, 2026 (P.L. 119-37) takes effect November 12, 2026, redefining hemp from a delta-9-only 0.3 percent standard to a total-THC standard that captures THCA and caps finished consumable products at 0.4 milligrams of total THC per container. Industry estimates suggest this could render the large majority of existing hemp-derived THC products federally illegal, and the U.S. Hemp Roundtable and others are lobbying for a delay. Because Pennsylvania has no comprehensive state intoxicating-hemp framework of its own, the federal change is the dominant near-term driver; SB 49 was explicitly framed as bringing state law into line with it. Sources: Vicente LLP, Harris Sliwoski Canna Law Blog, Cannabis Business Times (House farm bill).

Philadelphia is not waiting for Harrisburg. City Council passed Bill No. 260163 on June 4, 2026 by a 16 to 0 vote, restricting the sale of intoxicating hemp derived cannabinoid products citywide; as of July 16, 2026 the bill sits in the mayor’s office awaiting signature. The U.S. Hemp Roundtable reports the ordinance caps finished products at 0.4 milligrams of total THC per container, matching the federal standard that takes effect November 12, 2026. Sources: Philadelphia City Council record (Bill 260163), U.S. Hemp Roundtable.

Psychedelics

Psilocybin and other psychedelics remain illegal in Pennsylvania; psilocybin is a Schedule I controlled substance and possession is a criminal offense. There is no decriminalization. Source: AllowedHere.

The active 2025-2026 efforts are narrow and therapeutic/research-oriented rather than decriminalization. Republican Representative Tracy Pennycuick and Democratic Representative Jennifer O'Mara have pursued psilocybin legislation focused on veterans, first responders, and their families for conditions such as PTSD and traumatic brain injury. Reporting references a "Public Health Benefits of Psilocybin Act" and bill numbers including HB 1959 and HB 1439; the precise current bill number and status of each are unconfirmed and should be verified against the legislature's tracker before citing. In December 2025 a two-bill package was announced in the state Senate aimed at veteran access to PTSD treatment; sponsors and bill numbers for that package are unconfirmed. In September 2025 the House Democratic Policy Committee held a hearing on psilocybin for mental health. Sources: Marijuana Moment, Psychedelic Spotlight, WHYY, PA House co-sponsorship memo 46243.

Broader drug policy

Decriminalization: There is no statewide decriminalization of drug possession. Some municipalities (including Philadelphia and Pittsburgh) have locally reduced penalties or deprioritized enforcement for small-amount cannabis, but state criminal law still applies. Source: MPP Pennsylvania.

Harm reduction: Fentanyl test strips and other drug-checking equipment were legalized in 2022 when then-Governor Tom Wolf signed Act 111, removing test strips from the criminal-code list of prohibited drug paraphernalia after unanimous House and Senate passage. Statewide syringe services programs remain unauthorized by statute; Pennsylvania is one of roughly 12 states that do not explicitly authorize syringe services. Legalization bills have advanced in committee in prior sessions (a House committee voted 15-10 to create a paraphernalia exception) and a 2025 measure, House Bill 731, is described as syringe-services legislation, though its current status is unconfirmed and Republican opposition has repeatedly stalled the effort. Naloxone access has been broadened through a statewide standing order and pharmacy availability. Sources: Vital Strategies, Spotlight PA, PA House HB 731 page, WESA naloxone.

Sentencing and expungement: Pennsylvania's Clean Slate law (the nation's first automated record-sealing law) was expanded by Clean Slate 3.0, effective February 12, 2024. It provides automatic sealing of many summary and misdemeanor convictions and some low-level felonies after waiting periods (5 years for summary offenses, 7 years for many misdemeanors, 10 years for certain low-level drug and property felonies), subject to conditions. There is no cannabis-specific automatic expungement statute; relief for marijuana convictions currently runs through Clean Slate sealing and the expedited pardon process. Sources: Legal Aid of Southeastern PA (Clean Slate 3.0), Last Prisoner Project.

Political landscape

Governor: Josh Shapiro (Democrat), who has backed adult-use legalization in successive budget proposals and, per Senator Laughlin, lobbied Senate Democrats against SB 49 in June 2026. Source: Sen. Laughlin (SB 49 fails).

The November 2026 governor’s race puts the two positions on the ballot. Shapiro has proposed legalization in each of his budgets; State Treasurer Stacy Garrity, his Republican challenger, has said she would veto it. Sources: Philadelphia Inquirer, Broad and Liberty.

Legislature: split. The House is Democratic 102 to 100, with one seat (the 12th District) vacant ahead of an August 18, 2026 special election; the Senate is Republican 27-23, a majority the GOP has held since 1994. Republicans held 28 Senate seats after the 2024 election; Democrat James Malone won the March 25, 2025 special election in the 36th District following Ryan Aument’s resignation, narrowing the margin to 27-23. Source: PA Senate member roster, PA House member roster, Ballotpedia, PA Senate, WESA (12th District vacancy).

Key committee: the Senate Law and Justice Committee is the central gatekeeper for cannabis and hemp bills; it killed HB 1200 and is where SB 49 and SB 120 sit.

Named reform champions: Senator Dan Laughlin (R-Erie), chair of Senate Law and Justice, supports a privately licensed adult-use market and an intoxicating-hemp ban; Senator Sharif Street (D-Philadelphia), co-sponsor of SB 120; Representatives Rick Krajewski (D) and Dan Frankel (D), sponsors of the House state-store bill HB 1200. Representatives Tracy Pennycuick (R) and Jennifer O'Mara (D) lead the psilocybin effort. Named opponents/skeptics: Laughlin opposed the state-store model in HB 1200, and Governor Shapiro is reported to have urged Senate Democrats against SB 49; broader Senate Republican caucus resistance has repeatedly blocked legalization and syringe-services bills. Specific roll-call positions of individual rank-and-file members beyond those named are unconfirmed. Sources: MJBizDaily, MPP SB 120.

Ballot initiatives

Pennsylvania does not allow statewide citizen-initiated ballot measures or referenda. All policy changes must move through the General Assembly (constitutional amendments require legislative passage in two consecutive sessions plus a statewide vote, but there is no citizen initiative route). There are therefore no pending citizen-initiated drug-policy measures. Source: general PA constitutional structure; see Ballotpedia, PA General Assembly.

Equity and expungement

None of the failed or pending adult-use bills has yet become law, so social-equity licensing provisions remain prospective. The House state-store bill and the Senate SB 120 framework both contemplated social-equity and disproportionately impacted area provisions, and Governor Shapiro's budget proposals have referenced restorative-justice funding, small and diverse business support, and expungement for cannabis possession offenses. Until a bill passes, expungement/record relief operates through the existing Clean Slate 3.0 automated sealing regime (effective February 2024) and the expedited pardon process, neither of which is cannabis-specific and both of which exclude many higher-level offenses and impose multi-year waiting periods. Who is excluded today: people with disqualifying convictions, recent offenses, or offenses above the sealing thresholds, and anyone needing affirmative expungement rather than sealing. Sources: MPP SB 120 summary, Legal Aid of Southeastern PA, Foley Hoag.

Market and barriers

Hard numbers, medical market (no adult-use market exists yet): - Patients: approximately 440,000 active. - Operators: about 185 dispensaries and 30 growers/processors. - Taxes: no sales tax on medical cannabis. A 15 percent gross-receipts tax applies at the grower/processor to dispensary sale level under Act 16 (standard PA medical program structure); confirm current rate against state regulators before citing. - Sales: more than $1.3 billion in the first three quarters of 2025. - Prices: reported down about 49 percent since 2021. License caps, fees, and capital/residency requirements: Act 16 sets limited numbers of grower/processor and dispensary permits with substantial application fees and capital-on-hand requirements (historically six-figure fees and demonstrated capital in the millions for grower/processor permits); the microgrower pathway lowers some barriers. Exact current fee schedules and any residency requirements are unconfirmed here and should be verified with the PA Department of Health and the proposed Cannabis Control Board framework. Sources: Axios Philadelphia, MMJ.com guide, Cannabis Industry Lawyer.

Enclosure read

Pennsylvania sits toward the fenced end of the enclosure spectrum. The mature medical market is meaningfully fenced: a capped permit system favors incumbent vertically integrated operators and MSOs, home grow is banned outright (criminalizing the smallest, lowest-cost form of access), and patients with limited means are pushed toward dispensary purchase. On the other side, the long failure to pass adult-use legalization means the much larger consolidation event has not yet happened, and the intoxicating-hemp sector remains, for now, an open and competitive (if unregulated) market with many small retailers. The two live 2026 dynamics both point toward more enclosure: SB 49 would ban most intoxicating hemp products and hand oversight to a Cannabis Control Board, fencing out hundreds of small hemp retailers in favor of the regulated cannabis incumbents who back the ban, and the federal November 12, 2026 hemp deadline threatens to wipe out the small-operator hemp THC market nationally. Whoever ultimately writes the adult-use law (state-store versus private-license) will determine the next big consolidation. The score is 4/5: Pennsylvania offers neither adult-use nor any legal home cultivation, its medical market is capped and incumbent-dominated, and it has no citizen-initiative route to force change, the same profile as the medical-only states already scored 4. The one real open-access channel left, loosely regulated hemp, is set to close under the November 12 federal cliff, and every 2026 vector, driven by incumbents, prosecutors, and the federal deadline, points toward fencing out small operators. See how Pennsylvania compares to all 51 jurisdictions on the 50-State Matrix.

What to watch next

November 12, 2026: federal Section 781 hemp redefinition takes effect, the dominant near-term hemp deadline.
SB 49: no action since the June 10 reconsideration vote; watch whether a revote revives the bill or it dies with the session. This decides the state hemp ban and the Cannabis Control Board.
SB 120: still in Law and Justice; the June 29 discharge resolution (D.R. 4) is pending with no floor action as of July 16, 2026.
Budget: settled for the year. The $50.85 billion 2026-27 budget signed July 12, 2026 excluded legalization, closing the budget vehicle until 2027.
May 19, 2026 primary and the November 2026 general election: all 203 House seats and half the Senate are up; control of both chambers is contested and could reshape 2027 prospects. The governor’s race pairs Shapiro, who proposes legalization, against Stacy Garrity, who has said she would veto it.
Legislature: convened January 6, 2026; scheduled to adjourn the session around November 30, 2026. Sources: Vicente LLP, Schneider Downs 2026 PA session schedule, Spotlight PA (2026 control).

Regulators

Pennsylvania Department of Health, Office of Medical Marijuana: administers the current medical cannabis program.
Pennsylvania Department of Agriculture: administers the hemp program under the state hemp plan.
Proposed Pennsylvania Cannabis Control Board (under SB 49 / SB 120): would consolidate regulation of medical cannabis, hemp, and any future adult-use market; not yet created as of July 2026.
Pennsylvania Office of Attorney General (AG David Sunday): enforcement; AG has backed the intoxicating hemp ban. Sources: Penn Capital-Star (Cannabis Control Board explainer), Eckert Seamans.

Federal exposure (2026)

Pennsylvania's federal exposure is unusually concentrated on the hemp side, with a genuine but bounded upside on the cannabis tax side.

Rescheduling and 280E. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, while recreational cannabis stays Schedule I. Because Pennsylvania is a medical-only state with roughly 440,000 active patients and about 185 dispensaries and 30 growers/processors, its licensed operators fall squarely inside the medical category that gains relief. The practical effect is the end of Internal Revenue Code Section 280E for Pennsylvania's medical cannabis operators, who can now deduct ordinary business expenses, a material margin improvement in a market where patient prices have fallen about 49 percent since 2021. Drug Policy Watch has traced how that same federal relief is already being targeted for repeal in They Are Rebuilding Prohibition Out of the Tax Code. This relief flows disproportionately to the incumbent vertically integrated operators and multistate operators who hold the capped permits; it does nothing to legalize, to open interstate commerce, or to shelter state-licensed businesses from the residual federal illegality of the underlying activity. Pennsylvania has no adult-use market for Schedule III relief to reach, after repeated legalization failures (HB 1200 killed in committee in 2025, SB 120 unscheduled), so the 280E benefit is confined to the existing medical channel. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; it does not change the medical-only posture for Pennsylvania.

The November 12, 2026 hemp cliff. This is Pennsylvania's single largest federal exposure, and we track the national deadline in The Nov 12 Cliff. Section 781 of the FY2026 agriculture appropriations (P.L. 119-37, the Harris provision) narrows hemp to a total-THC standard capping finished consumable products at about 0.4 milligrams of total THC per container, effective November 12, 2026, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products nationally. The H.R.7010 delay was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban. Pennsylvania has no comprehensive state intoxicating-hemp framework of its own, so the federal redefinition is the dominant near-term driver. The state response, SB 49 (Sen. Dan Laughlin, R-Erie), would create a Cannabis Control Board and ban most intoxicating hemp THC, explicitly aligning state law with the new federal total-THC standard; on June 10, 2026 SB 49 failed final passage 23 to 27, a motion to reconsider passed 29-21, and no further action had been taken as of July 16, 2026. The two ban tracks interact: even if SB 49 dies in Harrisburg, the federal cliff alone would render most of the products in Pennsylvania's large, loosely regulated delta-8, delta-10, and THCA retail channel federally illegal as of November 12, 2026. The practical effect is that hundreds of independent Pennsylvania hemp retailers face product loss whether or not the state acts, and the regulated cannabis incumbents who back SB 49 stand to absorb that demand.

Banking. SAFER Banking remains stalled in Congress. Pennsylvania's medical operators therefore continue to face limited depository and lending access and cash-handling burdens; Schedule III rescheduling does not cure the banking problem, which is statutory and separate. This keeps capital costs high and favors well-capitalized incumbents over new or small entrants, reinforcing the capped-permit concentration.

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally; the April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review but there is no approval yet. Pennsylvania's own efforts are narrow and veteran or first-responder focused (the Pennycuick/O'Mara therapeutic-access bills, exact numbers unconfirmed) and are explicitly contingent on the federal/FDA route rather than state decriminalization. The federal lever, FDA approval and any down-scheduling, is the gating event for Pennsylvania access; nothing in the state pipeline operates independently of it.

Harm reduction. Pennsylvania legalized fentanyl test strips in 2022 (Act 111), and naloxone remains federally supported, so those tools are not directly threatened. But Pennsylvania still has no statutory authorization for syringe services programs, making it one of roughly 12 states without explicit authorization, and the SAMHSA guidance of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water. The practical effect is twofold: the SAMHSA cuts remove a federal funding stream that some Pennsylvania programs and partners rely on for the very supplies (test strips, sterile water, syringes) the state either permits or tolerates locally, and because Pennsylvania never built statutory syringe-services authorization, it has no state legal scaffold to backfill the federal retreat. Naloxone distribution, federally still supported, is the one harm-reduction lever insulated from the 2026 cuts.

Patient access and rights

This section covers what Pennsylvania law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Pennsylvania has no hospital-access law in force yet, and its pending bill is narrower than the name suggests. House Bill 2254 (Rep. Dan Frankel), Pennsylvania's version of Ryan's Law, would require hospitals, long-term care nursing facilities, assisted living residences, and personal care homes to let terminally ill patients use medical cannabis on the premises. It reaches only terminally ill patients, not the general patient population; it does not cover hospital emergency departments; it does not require a facility to administer the cannabis; and it bars smoking. It passed the Pennsylvania House 174 to 27 on June 1, 2026 and now goes to the state Senate. Until it is enacted and in force, no statute requires any Pennsylvania facility to permit a patient to use medical cannabis on site, so the decision is left to each facility's own policy and many refuse. Seven states have already enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026); Pennsylvania's bill is pending, not yet law.

Broader protections: Pennsylvania's are narrow, and they rest almost entirely on one section of the 2016 Medical Marijuana Act, 35 P.S. Section 10231.2103. That section bars employment discrimination against a certified patient based on their patient status (Section 2103(b)(1)), which is a real and enforceable shield at work. Parenting is less settled: Pennsylvania has no dedicated custody protection for patients. The Act's general anti-discrimination language, Section 2103(a), says a patient may not be denied any right or privilege for lawful use and may reach a custody case, but custody itself is decided under Title 23 Pa.C.S. Section 5328, which carries no cannabis carve-out, and reform is pending. Treat this as an open question, not a guarantee. On the remaining areas, a review of Section 2103 found no provision protecting housing, placement on an organ transplant list, school enrollment, or general medical care; on those a Pennsylvania patient has only the Act's general immunity to point to, not an explicit protection.

Out-of-state patients: Pennsylvania does not recognize other states' medical cannabis cards. The program serves Pennsylvania residents only, so a visiting patient cannot legally purchase at a Pennsylvania dispensary on an out-of-state card. Reciprocity rules change, so verify at the point of travel.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, which is what House Bill 2254 would begin to do, for terminally ill patients, if it becomes law. The protections above, and the gaps beside them, are creatures of Pennsylvania law, not federal law.

Sources: hospital-access bill, House Bill 2254; patient employment protection and general immunity, the Pennsylvania Medical Marijuana Act, 35 P.S. Section 10231.2103; child-custody standard, 23 Pa.C.S. Section 5328.

Analysis: the enclosure read in depth

Pennsylvania is a large medical market with a stalled adult-use fight, and the 2026 federal moves push the same way the state's own incumbents are pushing: toward enclosure.

Who is fenced out. The clearest losers are independent intoxicating-hemp retailers. The federal November 12, 2026 cliff alone, before any state action, recriminalizes most of their inventory; SB 49 would add a state ban on top. These are typically small, single-location or regional businesses with no permit pathway into the regulated cannabis market, which is capped under Act 16. Second, ordinary patients and would-be home cultivators are fenced out: home grow is banned outright for everyone including medical patients, so the cheapest form of access (a single plant) is a criminal offense, and there is no adult-use channel at all. Third, prospective small cannabis entrants are fenced out by the capped permit regime, six-figure fees, capital-on-hand requirements, and stalled banking; the microgrower pathway lowers but does not remove these barriers.

Who consolidates. The beneficiaries are the incumbent vertically integrated operators and multistate operators holding Act 16 permits. They gain three ways at once in 2026: 280E relief from Schedule III medical rescheduling improves their margins; the hemp ban (federal plus SB 49) removes a large, cheaper, unregulated competitor channel and pushes that demand toward licensed product; and stalled SAFER Banking keeps capital costs high in a way that favors the already-capitalized. The Pennsylvania Cannabis Coalition, the state Chamber, the District Attorneys Association, and the Attorney General backing the hemp ban illustrates the incumbent-plus-enforcement coalition that drives enclosure here.

State-plus-federal interaction. The federal levers do not merely sit alongside state policy; they amplify it. The hemp cliff gives the state ban political cover and makes it partly redundant (the products become federally illegal regardless), so even legislative gridlock in Harrisburg produces an enclosure outcome on hemp. On cannabis, federal Schedule III delivers a margin windfall to the exact incumbents the state permit cap already favors, while federal banking inaction preserves the capital moat. On harm reduction, the federal SAMHSA cuts expose a gap the state never closed (no statutory syringe services), so federal retreat and state inaction compound rather than offset.

What to watch. Whether SB 49 is revived after the motion to reconsider, and whether any adult-use bill (SB 120 private-license versus the HB 1200 state-store model) gets a hearing, since whoever writes the adult-use law writes the next big consolidation event. Watch how Pennsylvania hemp retailers respond to the November 12 federal cliff (litigation, pivoting to compliant low-THC products, or exit). Watch the May 19, 2026 primary and November 2026 general election, since all 203 House seats and half the Senate are up and chamber control could reshape 2027 prospects. Watch whether any state funding backfills the SAMHSA harm-reduction cuts.

Scarcity of commons counter-moves. The structural feature that makes Pennsylvania hard to de-enclose is the absence of a citizen ballot-initiative route; every change must clear a split legislature where the Senate Law and Justice Committee is a single gatekeeper. There is no home-grow right, no statewide decriminalization, and no statutory syringe-services authorization, so the usual commons counter-moves (citizen-initiated legalization, a personal-cultivation carve-out, a low-barrier microbusiness tier that actually scales, mandated patient-access protections) either do not exist or are weak. The only meaningful open-access features today are the still-unregulated hemp channel (which the federal cliff is about to close) and the modest microgrower pathway. One modest counter-move appeared on July 11, 2026: HB 2694 (Davidson) would reserve one added dispensary permit per region for small, diverse, or disadvantaged businesses; it sits in the House Health Committee.

Justifying the enclosure score of 4/5. Pennsylvania sits in the more-enclosed range and is trending further that way. It is not a 5 because a legal medical market exists and serves roughly 440,000 patients, and because the still-unregulated hemp channel plus locally tolerated municipal decriminalization leave some open-access space, for now. It is not a 3 because, unlike the states in that tier, Pennsylvania offers neither adult-use nor any legal home cultivation: growing a single plant is a criminal offense even for medical patients, the medical market is capped and dominated by vertically integrated operators and MSOs, and there is no citizen-initiative route to force change. That profile, medical-only with home grow banned and no ballot escape hatch, is the same one carried by the dozen states already scored 4, including Alabama, Georgia, Kentucky, Louisiana, and West Virginia. Every 2026 vector, the federal hemp cliff, the federal Schedule III margin windfall to incumbents, stalled banking, the SAMHSA harm-reduction cuts, and the incumbent-backed SB 49, points toward more enclosure, with essentially no countervailing commons mechanism available. A 4 places Pennsylvania with its structural peers: meaningfully fenced today, and closing.

Active legislation (2026)

This list covers significant active or recent 2026 bills and is not exhaustive. For the full long tail, see the live trackers linked below.

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB 49	Cannabis Control Board; intoxicating hemp ban added by March 2026 amendment	Senate	Failed final passage 23-27 (June 10, 2026); motion to reconsider passed 29-21; no further action as of July 16, 2026	Dan Laughlin (R-Erie)
SB 120	Adult-use legalization; private, state-licensed market under a Cannabis Control Board	Senate	In Senate Law and Justice Committee; discharge resolution (D.R. 4) filed by all 23 Democratic senators June 29, 2026; no floor action as of July 16, 2026	Dan Laughlin (R), Sharif Street (D)
HB 1200	Adult-use legalization via state-run (government) stores	House	Passed House (May 2025) by one vote; killed in Senate Law and Justice Committee 7-3 (May 13, 2025)	Rick Krajewski (D), Dan Frankel (D)
HB 2694	Medical marijuana equity permits; one added dispensary permit per region reserved for small, diverse, or disadvantaged businesses	House	Introduced July 11, 2026; referred to House Health	Nathan Davidson (D)
HB 731	Syringe services program legalization (paraphernalia exception)	House	Introduced; status unconfirmed	Sponsor unconfirmed
HB 1439 / HB 1959	Psilocybin therapeutic-access / research for veterans and first responders (bill numbers reported in sources; verify)	House	Pending; precise number and status unconfirmed	Tracy Pennycuick (R), Jennifer O'Mara (D)

Live trackers and long-tail references: LegiScan Pennsylvania, Pennsylvania General Assembly, Marijuana Moment Pennsylvania coverage.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →